Overall haemostatic potential can be used for estimation of thrombin-activatable fibrinolysis inhibitor-dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to factor VIII.

This paper describes a novel method for assessment of hemostasis (overall hemostatic potential, OHP) based on determination of the fibrin aggregation curve using a tiny amount of thrombin. OHP was used to measure thromin activatable fibrinolysis inhibitor (TAFI) before and after treatment with rFVIIa. It is thought that one of the mechanisms of action of […]

Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation.

Etiology of bleeding in cirrhotic patients during surgery is multifactorial, and its management includes several measures such as replacement of coagulation factors and platelets as well as the use of antifibrinolytic agents. Recombinant factor VIIa has been shown to normalize prothrombin time in patients with liver disease and to reduce transfusion requirement during OLT. In […]